Abstracts tagged "Biomarkers"

Abstract Number: 0341 • ACR Convergence 2022
Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice
YoungEun Kim¹, Eun-Ju Lee¹, Soo Min Ahn¹, Ji Seon Oh², Seokchan Hong¹, Chang Keun Lee¹, Bin Yoo¹ and Yong Gil Kim¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Despite improvements in the treatment of lupus nephritis (LN), the prognosis remains unsatisfactory, and a need for non-invasive biomarkers for early detection endures. Previously,…
Abstract Number: 0595 • ACR Convergence 2022
Validation of Urotensin-2 mRNA Expression as Marker for Tocilizumab Non-Response in Early Rheumatoid Arthritis
Janani Sundaresan¹, Ittai B. Muller¹, Marry Lin¹, Floris P.J.G. Lafeber², Paco Welsing², Maurits C.F.J. De Rotte³, Maja Bulatovic-Calasan⁴, Conny van der Laken⁵, Robert De Jonge⁶ and Gerrit Jansen⁵, ¹Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Clinical Chemistry, Amsterdam University Medical Centers – location AMC, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUmc, Amsterdam, The Netherlands; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁶Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Tocilizumab (TCZ), a biologic Disease Modifying Anti-Rheumatic Drug, elicits an immune-modulating effect by binding to the interleukin 6 receptor and inhibiting downstream signaling. Despite…
Abstract Number: 0830 • ACR Convergence 2022
Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis
Michael Manansala, Christian Ascoli and Nadera Sweiss, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by granuloma formation. Clinical manifestations are heterogenous, but most commonly affect the pulmonary system. Current biomarkers lack…
Abstract Number: 1048 • ACR Convergence 2022
Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study
Jacqueline Lemmers¹, Arjan van Caam², Brigit Kersten², Els Ende, van den², Hanneke KNAAPEN², Arie Dijk, van², Wanda Hagmolen of ten Have², Frank van den Hoogen², Hans Koenen², Sander van Leuven³, wynand Alkema⁴, Ruben Smeets² and Madelon Vonk⁵, ¹Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboud University, Nijmegen, Netherlands, ⁴Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, ⁵Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…
Abstract Number: 1389 • ACR Convergence 2022
The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
Patrick Garnero¹, Evelyne Gineyts¹, Jean-Charles Rousseau¹, Pascal Richette², Jérémie SELLAM³ and Roland Chapurlat¹, ¹INSERM 1033, Lyon, France, ²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: The prognosis of rheumatoid arthritis (RA) is highly variable across patients (P.) and difficult to predict. Usual risk factors, e.g., radiological joint damage, increased…
Abstract Number: 1519 • ACR Convergence 2022
Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
Erin Chew¹, Sarah Wood¹, Bibin Varghese¹, Christopher Chew², erin wilfong¹ and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Primary heart involvement in systemic sclerosis (SSc-pHI) is characterized by myocardial inflammation with resultant fibrosis that is not secondary to ischemic heart disease or…
Abstract Number: 1747 • ACR Convergence 2022
Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis
Cliff Rims¹, Virginia Muir¹, Anne Hocking¹, Sylvia Posso¹, Heather Bukiri², Jeffrey Carlin³, Bernard Ng⁴, Peter Linsley¹, Eddie James⁵ and Jane Buckner⁵, ¹Benaroya Research Institute, Seattle, WA, ²University of California Los Angeles, Los Angeles, CA, ³Virginia Mason Medical Center, Seattle, WA, ⁴VA Puget Sound HCS, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: In Rheumatoid arthritis (RA) citrullinated antigen reactive T cells are key drivers of disease, but knowledge about their relative number and phenotype remains limited.…
Abstract Number: 1962 • ACR Convergence 2022
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Daniel Kass¹, Mehdi Nouraie¹, Yingze Zhang¹, Bryant England², Ted Mikuls³, Gail Kerr⁴, Andreas Reimold⁵, Kevin Gibson¹, Marilyn Glassberg⁶, Paul Dellaripa⁷, Tracy Doyle⁷, Chester Oddis⁸ and Dana Ascherman⁸, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵North Texas Veterans Administration Health Care System, Dallas, TX, ⁶Loyola University Chicago Stritch School of Medicine, Chicago, IL, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…
Abstract Number: 2148 • ACR Convergence 2022
Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis
Mathias Cardner¹, Danny Tuckwell², Anna Kostikova², Pascal Forrer³, Richard Siegel², Alain Marti³, Marc Vandemeulebroecke³ and Enrico Ferrero², ¹Novartis Global Drug Development and Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Novartis Global Drug Development, Basel, Switzerland
Background/Purpose: Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking.Methods:…
Abstract Number: 0120 • ACR Convergence 2022
Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
Carla J. Guthridge¹, Catriona Wagner², Sohail Khan³, Michael Peercy⁴, Bobby Saunkeah⁴, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Cherokee Nation, Tahlequah, OK, ⁴Chickasaw Nation, Ada, OK
Background/Purpose: EBV infection is associated with autoantibody development in the preclinical period of rheumatic diseases, such as SLE and RA. Furthermore, EBV reactivation, characterized by…
Abstract Number: 0360 • ACR Convergence 2022
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Mark Lazarus¹, Paul Newcombe¹, Richard A. Furie², Philip Brohawn³, Wendy White³, Dominic Sinibaldi³, Nicola Ferrari¹, Raj Tummala³, Hussein Al-Mossawi¹, Edward Vital⁴, Eric F. Morand⁵, Daniel Muthas⁶ and Madhu Ramaswamy³, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³AstraZeneca, Gaithersburg, MD, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Monash University, Melbourne, Australia, ⁶AstraZeneca, Gothenburg, Sweden
Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…
Abstract Number: 0602 • ACR Convergence 2022
Cellworks Biosimulation Model (CBM) for Rheumatoid Arthritis (RA), Accurately Captures Patient’s Disease Activity at the Molecular Level Using Their Omics Data and Can Bring Personalization to Treatment Selection in RA
Himanshu Grover¹, Ansu Kumar¹, Anushua Chakraborty¹, Susheel George Chandy¹, Vivek Patil¹, Swati Khandelwal¹, Vishwas Joseph¹, Deepak Anil Lala¹, Prashant Ramachandran Nair¹, Karthik Sundara Raju¹, Kunal Ghosh Roy¹, Shahabuddin Usmani¹, Aftab Alam¹, Swaminathan Rajagopalan¹, Yatin Mundkur¹ and Andrew Concoff², ¹Cellworks Group Inc., South San Francisco, CA, ²United Rheumatology, Hauppauge, NY
Background/Purpose: Patients with RA demonstrate varied individual responses to the many treatment options available. In the absence of accurate, precision prediction of medication response, current…
Abstract Number: 0836 • ACR Convergence 2022
Bone Turnover and Physical Activity Before and After Anterior Cruciate Ligament Reconstruction
Elizabeth Wellsandt¹, David Werner¹, Mikayla McKee², Matthew Tao², Kaleb Michaud¹ and Yvonne Golightly¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha
Background/Purpose: Individuals after anterior cruciate ligament reconstruction (ACLR) have 8 times higher odds of developing knee osteoarthritis (OA) within 10 years compared to those with…
Abstract Number: 1116 • ACR Convergence 2022
Peripheral Blood DNA Methylation-based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biospecimens and Data from the Osteoarthritis Initiative and Johnston County Osteoarthritis Project
Chris Dunn¹, Cassandra Sturdy², Cassandra Velasco³, Leoni Schlupp², Emmaline Prinz², Vladislav Izda⁴, Liubov Arbeeva⁵, Yvonne Golightly⁶, Amanda Nelson⁷ and Matlock Jeffries², ¹University of Oklahoma Health Sciences Center, Edmond, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, New York, NY, ⁵University of North Carolina Chapel Hill, Chapel Hill, NC, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes, for which there exist no widely-available biomarkers. We…
Abstract Number: 1400 • ACR Convergence 2022
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Tate Johnson¹, Rebekah Gundry², Merry Lindsey², Punyasha Roul³, Yangyuna Yang², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Geoffrey Thiele², Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in patients with rheumatoid arthritis (RA). General population CVD risk calculators underestimate risk in RA,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].